Publication:
Enhanced HIV-1 Neutralizing Antibody Breadth in HTLV-2 Co-Infected Individuals: Influence of Antiretroviral Regimen and B Cell Subset Distribution.

dc.contributor.authorYuste, Eloisa
dc.contributor.authorRuiz-De-León, María J
dc.contributor.authorCasado, José L
dc.contributor.authorMoreno, Ana
dc.contributor.authorVivancos, María J
dc.contributor.authorPérez-Elías, María J
dc.contributor.authorDronda, Fernando
dc.contributor.authorQuereda, Carmen
dc.contributor.authorSanchez-Merino, Victor
dc.contributor.authorVallejo, Alejandro
dc.contributor.funderInstituto de Salud Carlos III
dc.date.accessioned2026-11-11T13:32:22Z
dc.date.available2026-11-11T13:32:22Z
dc.date.issued2025-06-13
dc.description.abstractBackground/objectives: This study aimed to explore how HTLV-2 infection affects the production of broadly neutralizing antibodies (bNAbs) in persons with HIV-1 (PWH) and to assess the impact of boosted protease inhibitors (PIs). Methods: We evaluated broadly neutralizing antibody (bNAb) activity in 65 PWH, which included 27 who were also co-infected with HTLV-2. All participants were former injection drug users with HCV antibodies and were receiving suppressive antiretroviral therapy (ART). Neutralizing activity was assessed against six recombinant HIV-1 viruses that represent five different subtypes. B cell subsets were also analyzed. Results: HTLV-2 co-infection and the lack of ritonavir-boosted protease inhibitors (r-PIs) were both independently associated with higher neutralization scores (p = 0.017 and p = 0.005, respectively). Among those not on r-PIs, individuals co-infected with HTLV-2 showed significantly higher neutralization scores (p = 0.027) and a broader neutralization breadth (83.4% vs. 48.5%, p = 0.015) compared to those infected only with HIV-1. Additionally, HTLV-2 co-infected individuals had more resting memory B cells (p = 0.001) and fewer activated memory B cells (p = 0.017) than the HIV-1 mono-infected individuals. In our multivariate analysis, only HTLV-2 co-infection remained independently associated with neutralization scores (p = 0.027). Elite neutralizers (with a breadth score of ≥10) had more naive B cells and fewer resting memory B cells compared to those with weaker neutralization in both groups. Conclusions: Co-infection with HTLV-2 enhances bNAb production in PWH on suppressive ART and, in particular, in the absence of r-PI regimens. The prominent neutralizing activity corresponded with B cell subset distributions. The results suggest the complexity regarding the interaction between viral co-infections, antiretroviral regimens, and humoral immune compartments and may inform further H1V-1 pathogenesis inquiries or the appropriate design of a vaccine.
dc.description.peerreviewedSí
dc.description.sponsorshipThis research was partially supported by a grant from Spanish Instituto de Salud Carlos III (PI20CIII/00039) awarded to E.Y.
dc.format.number6
dc.format.volume13
dc.identifier.citationYuste, E.; Ruiz-De-León, M.J.; Casado, J.L.; Moreno, A.; Vivancos, M.J.; Pérez-Elías, M.J.; Dronda, F.; Quereda, C.; Sánchez-Merino, V.; Vallejo, A. Enhanced HIV-1 Neutralizing Antibody Breadth in HTLV-2 Co-Infected Individuals: Influence of Antiretroviral Regimen and B Cell Subset Distribution. Vaccines 2025, 13, 639. https://doi.org/10.3390/vaccines13060639
dc.identifier.doi10.3390/vaccines13060639
dc.identifier.issn2076-393X
dc.identifier.journalVaccines
dc.identifier.pubmedID40573970
dc.identifier.urihttps://hdl.handle.net/20.500.12105/27823
dc.language.isoeng
dc.publisherMultidisciplinary Digital Publishing Institute (MDPI)
dc.relation.projectIDinfo:eu-repo/grantAgreement/ISCIII/AESI/PI20CIII%2F00039//Nuevos Abordajes para el Diseño de Inmunógenos para la Inducción de Anticuerpos Neutralizantes de Amplio Espectro anti-VIH-1 Basados en Envueltas Virales Presentadas en VLPs/
dc.relation.publisherversionhttps://doi.org/10.3390/vaccines13060639
dc.repisalud.centroISCIII::Centro Nacional de Microbiología (CNM)
dc.repisalud.institucionISCIII
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectB cell subsets
dc.subjectHIV-1
dc.subjectHTLV-2
dc.subjectNeutralizing antibodies
dc.titleEnhanced HIV-1 Neutralizing Antibody Breadth in HTLV-2 Co-Infected Individuals: Influence of Antiretroviral Regimen and B Cell Subset Distribution.
dc.typeresearch article
dc.type.hasVersionVoR
dspace.entity.typePublication
relation.isAuthorOfPublication1e723484-61b4-4f8f-ad19-48873c9050f5
relation.isAuthorOfPublication2c8533e8-d63c-4c22-9a9b-b630525f7153
relation.isAuthorOfPublication.latestForDiscovery1e723484-61b4-4f8f-ad19-48873c9050f5
relation.isFunderOfPublication7d739953-4b68-4675-b5bb-387a9ab74b66
relation.isFunderOfPublication.latestForDiscovery7d739953-4b68-4675-b5bb-387a9ab74b66
relation.isPublisherOfPublication30293a55-0e53-431f-ae8c-14ab01127be9
relation.isPublisherOfPublication.latestForDiscovery30293a55-0e53-431f-ae8c-14ab01127be9

Files

Original bundle

Now showing 1 - 2 of 2
Loading...
Thumbnail Image
Name:
EnhancedHIV-1NeutralizingAntibody_2025.pdf
Size:
1.6 MB
Format:
Adobe Portable Document Format
Loading...
Thumbnail Image
Name:
Supplementary_EnhancedHIV-1NeutralizingAntibody_2025.zip
Size:
615.45 KB
Format: